2021
DOI: 10.1088/1742-6596/1762/1/012009
|View full text |Cite
|
Sign up to set email alerts
|

Curcumin loaded casein submicron-sized gels as drug delivery systems

Abstract: Hydrogels from natural polyelectrolytes possess many important features such as low toxicity, biocompatibility, biodegradability and hydrophilicity. These properties make them very suitable for applications such as immobilization and controlled release of drugs and other types of biologically active molecules. In the present study submicron-sized hydrogels made from casein by ionotropic gelation are investigated. For this purpose, two types of crosslinking agents are used at different pH conditions. In order t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 22 publications
0
2
0
Order By: Relevance
“…In another trial, 50 patients received a single intravenous dose of liposomal curcumin in the range of 10–400 mg/m 2 over 2 h. While the dosages ≥120 mg/m 2 already changed the red blood cell morphology, the curcumin and its metabolites in plasma became undetectable within 6–60 min [ 19 ]. In order to improve the bioavailability of curcumin, a variety of nanocarriers for curcumin have been developed [ 20 , 21 , 22 ], including polymer micelles [ 23 , 24 , 25 , 26 ], liposomes [ 27 , 28 , 29 , 30 ], inorganic nanoparticles [ 31 , 32 , 33 ], porous silica/metal–organic frames [ 34 , 35 , 36 ], biopolymer complexes/nanoparticles [ 37 , 38 , 39 , 40 , 41 ], and nanogels [ 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 ]. However, most of these nanocarriers developed so far exhibit a low loading capacity, which still limits the bioavailability of curcumin for clinical use.…”
Section: Introductionmentioning
confidence: 99%
“…In another trial, 50 patients received a single intravenous dose of liposomal curcumin in the range of 10–400 mg/m 2 over 2 h. While the dosages ≥120 mg/m 2 already changed the red blood cell morphology, the curcumin and its metabolites in plasma became undetectable within 6–60 min [ 19 ]. In order to improve the bioavailability of curcumin, a variety of nanocarriers for curcumin have been developed [ 20 , 21 , 22 ], including polymer micelles [ 23 , 24 , 25 , 26 ], liposomes [ 27 , 28 , 29 , 30 ], inorganic nanoparticles [ 31 , 32 , 33 ], porous silica/metal–organic frames [ 34 , 35 , 36 ], biopolymer complexes/nanoparticles [ 37 , 38 , 39 , 40 , 41 ], and nanogels [ 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 ]. However, most of these nanocarriers developed so far exhibit a low loading capacity, which still limits the bioavailability of curcumin for clinical use.…”
Section: Introductionmentioning
confidence: 99%
“…In another trial, 50 patients received a single intravenous dose of liposomal curcumin in the range of 10-400 mg/m 2 over 2 h. While the dosages ≥120 mg/m 2 already changed the red blood cell morphology, the curcumin and its metabolites in plasma became undetectable within 6-60 min [19]. In order to improve the bioavailability of curcumin, a variety of nanocarriers for curcumin have been developed [20][21][22], including polymer Gels 2023, 9, 762 2 of 18 micelles [23][24][25][26], liposomes [27][28][29][30], inorganic nanoparticles [31][32][33], porous silica/metalorganic frames [34][35][36], biopolymer complexes/nanoparticles [37][38][39][40][41], and nanogels [42][43][44][45][46][47][48][49][50][51]. However, most of these nanocarriers developed so far exhibit a low loading capacity, which still limits the bioavailability of curcumin for clinical use.…”
Section: Introductionmentioning
confidence: 99%